Neuroblastoma (NB) is a paediatric form of cancer derived from the sympathetic nervous system. Recent genome-wide sequencing data suggest that often NB does not have a clear genetic cause, leading the authors to hypothesize that NB results from aberrations of normal development. To test this hypothesis, Anna Philpott's group used a population of anteroventral noradrenergic (AVNA) cells from Xenopus embryos. These cells share several features with mammalian sympathetic neurons, including the expression of noradrenergic-associated genetic markers such as the achaete-scute complex-like 1 (Ascl1) gene, which encodes a transcriptional driver of neurogenesis. By comparing AVNA and NB cells, the authors found that, whereas Ascl1 is only transiently expressed in AVNA cells, it is aberrantly maintained in NB, where it is phosphorylated on multiple serine-proline sites. The authors then show that differentiation of AVNA cells is enhanced by dephosphorylated Ascl1. Moreover, this process is inhibited by experimental manipulations of NB-associated genes, but, interestingly, dephosphorylation of Ascl1 is able to overcome this inhibition. This work demonstrates that Xenopus AVNA cells represent a unique system to study sympathetic nervous system development and its relationship to NB. Moreover, it suggests that Asc11 phosphorylation might promote stalled differentiation leading to NB, thus identifying a potential target for therapeutic purposes. Page
Skip Nav Destination
Article navigation
May 2015
Virtual Meeting - Developmental Disorders: From Mechanism to Treatment
A collaboration between the Development and Disease Models & Mechanisms journal teams, this virtual Meeting will unite developmental biologists, human geneticists and clinical researchers to focus on building bridges from bench to clinic. Register your interest and find out more.
High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition
Vitamin B1 is shown to prevent nutrition-induced fatty liver in our current Editor’s choice by Hay Davir and his colleagues, when they use sheep as a large-animal model for studying the disease.
Find out more in an interview with the paper's first authors, Mugagga Kalyesubula and Ramgopal Mopuri.
Upcoming grant deadlines
Call for papers - The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is welcoming submissions until 3 May 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on targeting the RAS pathway.
Social media
